enGene Therapeutics Inc. insiders have been one-way buyers this past year: one person put roughly $10,000 into the stock and nobody sold at market prices.
Grossman William (Executive Officer) made the biggest buy, worth around $10,000.
56 investment managers listed ENGN in their latest 13F filings (Q2 2026); more funds bought than sold. Quarter by quarter: Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | Grossman William | Executive Officer | Buy | 5,102 | $1.97 | $10K | SEC |
| Nov 1, 2024 | Forbion Growth Management B.V. | 10% Owner | Buy | 561,797 | $8.90 | $5.0M | SEC |
| Oct 18, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | Buy | 11,844 | $6.55 | $78K | SEC |
| Oct 18, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | Buy | 800 | $6.60 | $5K | SEC |
| Oct 18, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | Buy | 2,750 | $7.17 | $20K | SEC |
| Oct 18, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | Buy | 5,050 | $7.69 | $39K | SEC |
| Oct 18, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | Buy | 400 | $8.30 | $3K | SEC |
| Oct 18, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | Buy | 9,620 | $9.09 | $87K | SEC |
| Oct 18, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | Buy | 38,396 | $5.94 | $228K | SEC |
| Oct 18, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | Buy | 3,243 | $6.38 | $21K | SEC |
| Oct 18, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | Buy | 341,332 | $6.34 | $2.2M | SEC |
| Oct 18, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | Buy | 35,279 | $6.44 | $227K | SEC |
| Oct 18, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | Buy | 10,153 | $6.37 | $65K | SEC |
| Oct 18, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | Buy | 5,769 | $6.48 | $37K | SEC |
| Oct 18, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | Buy | 5,997 | $6.54 | $39K | SEC |
In the last 12 months enGene Therapeutics Inc. insiders made open-market purchases worth about $10,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in ENGN was filed on 2026-09-24.
56 investment managers reported holding ENGN in SEC Form 13F filings for Q2 2026.
No congressional trades in ENGN were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).